Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Clinical trial NCT01397708 · COMPLETED
Trial details
- NCT number
- NCT01397708
- Sponsor
- Alaunos Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-08-01
- Primary completion
- 2014-09-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.